Revital Kariv

Title: Revital Kariv: Innovator in Angiogenesis Inhibition

Introduction

Revital Kariv is a prominent inventor based in Bellevue, WA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies that inhibit angiogenesis. Her work has the potential to impact various therapeutic areas, including cancer treatment.

Latest Patents

Revital Kariv holds a patent for "Antibodies of angiogenesis inhibiting domains CD148." This patent describes anti-CD148 antibodies and antigen-binding regions, as well as pharmaceutical compositions that include these antibodies. The patent also outlines methods for using these antibodies to bind CD148 epitopes and activate CD148 function, which is crucial for inhibiting angiogenesis. Additionally, it details epitopes that can activate CD148 function and methods for identifying compounds that can bind them.

Career Highlights

Kariv's career is marked by her innovative research and development efforts at Amgen Inc. She has focused on creating solutions that address critical health challenges through her expertise in biotechnology and antibody development.

Collaborations

Revital collaborates with notable colleagues, including James F. Smothers and William C. Fanslow, III. These partnerships enhance her research capabilities and contribute to the advancement of her projects.

Conclusion

Revital Kariv is a trailblazer in the field of angiogenesis inhibition, with a patent that showcases her innovative approach to biotechnology. Her work at Amgen Inc. and collaborations with esteemed colleagues further solidify her impact in the industry.